1. Home
  2. PASG vs DRRX Comparison

PASG vs DRRX Comparison

Compare PASG & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PASG
  • DRRX
  • Stock Information
  • Founded
  • PASG 2017
  • DRRX 1998
  • Country
  • PASG United States
  • DRRX United States
  • Employees
  • PASG N/A
  • DRRX N/A
  • Industry
  • PASG Biotechnology: Pharmaceutical Preparations
  • DRRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PASG Health Care
  • DRRX Health Care
  • Exchange
  • PASG Nasdaq
  • DRRX Nasdaq
  • Market Cap
  • PASG 31.1M
  • DRRX N/A
  • IPO Year
  • PASG 2020
  • DRRX 2000
  • Fundamental
  • Price
  • PASG $0.39
  • DRRX $0.80
  • Analyst Decision
  • PASG Strong Buy
  • DRRX Buy
  • Analyst Count
  • PASG 3
  • DRRX 2
  • Target Price
  • PASG $7.67
  • DRRX $5.00
  • AVG Volume (30 Days)
  • PASG 162.1K
  • DRRX 46.3K
  • Earning Date
  • PASG 03-04-2025
  • DRRX 03-26-2025
  • Dividend Yield
  • PASG N/A
  • DRRX N/A
  • EPS Growth
  • PASG N/A
  • DRRX N/A
  • EPS
  • PASG N/A
  • DRRX N/A
  • Revenue
  • PASG N/A
  • DRRX $2,031,000.00
  • Revenue This Year
  • PASG N/A
  • DRRX $77.06
  • Revenue Next Year
  • PASG N/A
  • DRRX $488.85
  • P/E Ratio
  • PASG N/A
  • DRRX N/A
  • Revenue Growth
  • PASG N/A
  • DRRX N/A
  • 52 Week Low
  • PASG $0.33
  • DRRX $0.70
  • 52 Week High
  • PASG $1.64
  • DRRX $1.88
  • Technical
  • Relative Strength Index (RSI)
  • PASG 36.52
  • DRRX 48.02
  • Support Level
  • PASG $0.33
  • DRRX $0.79
  • Resistance Level
  • PASG $0.54
  • DRRX $0.87
  • Average True Range (ATR)
  • PASG 0.05
  • DRRX 0.03
  • MACD
  • PASG -0.00
  • DRRX -0.00
  • Stochastic Oscillator
  • PASG 24.29
  • DRRX 22.22

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Share on Social Networks: